Northwire Canada EditionTuesday, July 14, 2026
Sign inSubscribe
Northwire
⌕
WDO 26.04 −0.9% FVI 11.84 −1.6% OM 1.75 −1.7% ETG 2.99 +0.0% ARTG 31.47 −4.6% LUC 0.163 +1.6% AFM 1.38 +0.0% IMG 20.95 −3.5% CPAU 0.150 +3.5% MMX 0.075 +7.1% IE 12.47 −2.4% SASK 1.09 −1.8% MOG 0.390 +2.6% XIM 0.070 −6.7% S 0.110 −29.0% OMI 0.300 −4.8% WDO 26.04 −0.9% FVI 11.84 −1.6% OM 1.75 −1.7% ETG 2.99 +0.0% ARTG 31.47 −4.6% LUC 0.163 +1.6% AFM 1.38 +0.0% IMG 20.95 −3.5% CPAU 0.150 +3.5% MMX 0.075 +7.1% IE 12.47 −2.4% SASK 1.09 −1.8% MOG 0.390 +2.6% XIM 0.070 −6.7% S 0.110 −29.0% OMI 0.300 −4.8%

Healthcare

Page 45
  1. Mar 19, 2026 · 17:30 · RX

    BioSyent Releases Financial Results for Fourth Quarter and Full Year 2025

    BioSyent Releases Financial Results for Fourth Quarter and Full Year 2025

    01
  2. Mar 19, 2026 · 17:00 · APS

    Aptose Biosciences garners ISS nod for Hanmi deal

    Aptose Biosciences garners ISS nod for Hanmi deal

    02
  3. Mar 19, 2026 · 12:19 · AIAI

    Netramark finds AI defined responder groups in A4 trial

    Netramark finds AI defined responder groups in A4 trial

    03
  4. Mar 19, 2026 · 08:05 · MBIO

    MindBio Announces Upsize to Private Placement up to $1.5 Million

    MindBio Announces Upsize to Private Placement up to $1.5 Million

    04
  5. Mar 19, 2026 · 07:30 · APS

    Leading Independent Proxy Advisory Firm ISS Recommends Aptose Biosciences Shareholders Vote "FOR" Proposed Plan of Arrangement with Hanmi Pharmaceutical

    Leading Independent Proxy Advisory Firm ISS Recommends Aptose Biosciences Shareholders Vote "FOR" Proposed Plan of Arrangement with Hanmi Pharmaceutical

    05
  6. Mar 19, 2026 · 07:30 · GUD

    Knight Therapeutics Reports Fourth Quarter and Year-End 2025 Results

    Knight Therapeutics Reports Fourth Quarter and Year-End 2025 Results

    06
  7. Mar 19, 2026 · 07:00 · AIAI

    NetraMark Unveils AI-Discovered Treatment-Responsive Subgroups in A4 Alzheimer's Trial at AD/PD Conference

    NetraMark Unveils AI-Discovered Treatment-Responsive Subgroups in A4 Alzheimer's Trial at AD/PD Conference

    07
  8. Mar 19, 2026 · 06:30 · WELL

    WELL Health Reports Record FY2025 Results; Canadian Patient Services Adjusted EBITDA Up 43% with Record Free Cash Flow

    WELL Health Reports Record FY2025 Results; Canadian Patient Services Adjusted EBITDA Up 43% with Record Free Cash Flow

    08
  9. Mar 18, 2026 · 20:20 · NVRS

    Noveris Announces Closing of Life Offering

    Noveris Announces Closing of Life Offering

    09
  10. Mar 18, 2026 · 18:23 · VHI

    VitalHub Reports Fourth Quarter 2025 Results

    VitalHub Reports Fourth Quarter 2025 Results

    10
  11. Mar 18, 2026 · 18:04 · VVTM

    VVT Med Announces Private Placement of Units

    VVT Med Announces Private Placement of Units

    11
  12. Mar 18, 2026 · 16:47 · XRTX

    XORTX Therapeutics proposes three director nominees

    XORTX Therapeutics proposes three director nominees

    12
  13. Mar 18, 2026 · 16:35 · MRVL

    Marvel Biosciences obtains U.S. patent for drug MB-204

    Marvel Biosciences obtains U.S. patent for drug MB-204

    13
  14. Mar 18, 2026 · 12:03 · CHS

    Comprehensive Healthcare to add AI features to Novus

    Comprehensive Healthcare to add AI features to Novus

    14
← Newer Older →